More importantly, mice injected with CD81+ Erys-cocultured Egln3_KO AML cells exhibited markedly slower disease progression, with fewer PB AML cells (Figure 7K and Supplemental Figure 8N) and longer survival (Figure 7L). The gene discussed is CD81; the disease is acute myeloid leukemia.